Can Retatrutide Cause Depression?

Retatrutide is an investigational triple receptor agonist developed by Eli Lilly that has no marketing authorisation in the UK or elsewhere. Questions about whether retatrutide can cause depression are understandable given the scrutiny applied to GLP-1 receptor agonist medicines in recent years. Published trial data do not establish a confirmed causal link between retatrutide and depression, though mental health is routinely monitored within trial protocols. This article summarises what current evidence shows, who may be at greater risk of mood changes, and what participants or interested readers should know about reporting concerns.

What is retatrutide and what is its current status in the UK?

Retatrutide has no UK marketing authorisation and can only be accessed within an authorised clinical trial; it cannot be obtained through a GP, pharmacy or private clinic.

Retatrutide holds no marketing authorisation in the UK or anywhere else, and it can be prescribed or supplied only within an authorised clinical trial.^[1][2] It is an investigational medicine developed by Eli Lilly that acts simultaneously on three hormone receptors: the glucagon-like peptide-1 (GLP-1) receptor, the glucose-dependent insulinotropic polypeptide (GIP) receptor, and the glucagon receptor. This triple agonist mechanism is designed to influence appetite regulation, energy expenditure and glucose metabolism, though its clinical profile is still being characterised through ongoing research.

Because retatrutide has no UK marketing authorisation, the MHRA has not evaluated it for routine clinical use, and no Integrated Care Board (ICB) has commissioned it. It cannot be obtained through a GP, a pharmacy or a private clinic outside a trial setting. Anyone who encounters retatrutide being sold online should be aware that such a product is not a licensed medicine and may be falsified or unsafe.

For those interested in licensed weight-management treatments, options do exist and can be discussed with a GP. The Phase 3 trial programme for retatrutide, which includes the TRIUMPH and TRANSCEND studies, is generating data that regulators will eventually review, but no authorisation date can be given.^[4]

What do clinical trials say about retatrutide and mental health?

Published trial data do not confirm a causal link between retatrutide and depression; the most commonly reported adverse events have been gastrointestinal rather than psychiatric.

Current published trial data do not establish a confirmed causal link between retatrutide and depression, though mental health outcomes are routinely monitored in obesity and diabetes trials. The Phase 2 trial published in the New England Journal of Medicine in 2023 reported on safety and tolerability in participants with obesity, and the Phase 3 TRIUMPH and TRANSCEND programmes are generating further safety data; results from individual studies within these programmes have been presented at congresses and in peer-reviewed publications, though the full dataset remains incomplete. Across published data, the most commonly reported adverse events have been gastrointestinal in nature rather than psychiatric.^[1][2]

That said, the absence of a confirmed signal does not mean mental health effects have been ruled out. Following post-marketing observations with other GLP-1 receptor agonist medicines, the European Medicines Agency's Pharmacovigilance Risk Assessment Committee (PRAC) conducted a review and concluded in 2024 that available evidence did not confirm a causal association between GLP-1 receptor agonists and suicidal ideation or self-harm, while recommending continued monitoring.^[5][6] Because retatrutide activates GLP-1 receptors alongside GIP and glucagon receptors, similar vigilance is applied within its trial protocols as a matter of class-level caution.

It is also important to recognise that weight loss itself, rapid changes in appetite, and the psychological experience of participating in a clinical trial can all influence mood. Disentangling a drug effect from these contextual factors requires careful trial design and longer follow-up periods. Participants in retatrutide trials who notice changes in mood, low mood, anxiety or unusual thoughts are expected to report these promptly to the trial team, as adverse event reporting within a clinical trial follows the study protocol rather than standard clinical channels.

Who may be at greater risk of mood changes during trials?

People with a personal or family history of depression or anxiety carry greater baseline risk; active, unstable psychiatric conditions are typically an exclusion criterion for retatrutide trials.

People with a personal or family history of depression, anxiety or other mood disorders may be at greater baseline risk of experiencing mood changes during any clinical trial, including those involving investigational weight-management medicines such as retatrutide. Trial eligibility criteria typically exclude individuals with active, unstable psychiatric conditions, partly to protect participant safety and partly to reduce confounding in the safety data; readers wishing to confirm the specific criteria for individual TRIUMPH or TRANSCEND studies can consult the relevant entries on ClinicalTrials.^[4]gov. This means the trial populations studied so far may not fully represent people with more complex mental health histories.

Rapid weight loss, which has been observed in retatrutide trial participants, can itself be associated with psychological adjustment. Changes in body image, social relationships and self-perception can accompany significant weight reduction, and these factors may interact with underlying vulnerability to low mood. Whether the glucagon receptor component of retatrutide's mechanism has any direct effect on the central nervous system is not established in published data and remains a hypothesis requiring further investigation.

Additionally, people who are breastfeeding, pregnant or planning pregnancy are excluded from retatrutide trials, and contraception requirements apply to participants of childbearing potential during the study period; the specific requirements are set out in each trial protocol. Hormonal contraception and the physiological changes of the reproductive cycle can themselves influence mood, adding another layer of complexity when interpreting any psychiatric signals in trial data. Anyone with concerns about their mental health in the context of a clinical trial should raise them with the trial team without delay, as participant welfare is a primary obligation of the trial investigators.

What are the known and suspected side effects of retatrutide?

The most consistently reported side effects are gastrointestinal, including nausea, vomiting and diarrhoea; no causal relationship between retatrutide and depression has been established in published data.

The most consistently reported side effects of retatrutide in published trial data are gastrointestinal, including nausea, vomiting, diarrhoea and constipation, which are broadly consistent with the GLP-1 receptor agonist class. The Phase 2 trial published in the New England Journal of Medicine in 2023 described these effects as generally mild to moderate in severity and more common during dose escalation phases. Injection-site reactions have also been reported.

Acute pancreatitis has been reported in association with GLP-1 receptor agonist class medicines, including post-marketing reports of necrotising pancreatitis.^[9] Participants in retatrutide trials are monitored for symptoms such as persistent severe abdominal pain, and any such symptom should be reported to the trial team immediately. Gallbladder-related events, including gallstones, have also been observed with medicines in this class and are monitored accordingly.^[10][11]

With respect to mental health specifically, no definitive causal relationship between retatrutide and depression has been established in published trial data. Because the full safety profile of an investigational medicine is not known until large-scale, long-term data are available, all adverse events, including mood changes, low mood or thoughts of self-harm, must be reported to the trial team under the study protocol. Suspected side effects from medicines used within a clinical trial should be reported to the trial team in the first instance; the Yellow Card scheme at yellowcard.mhra.gov.uk is available for reporting suspected side effects from medicines taken outside a trial.

Trial participants should carry their trial identification card at all times and tell any emergency clinician that they are enrolled in a clinical trial before receiving any additional treatment. Anyone outside a trial who is experiencing depression or a significant change in mood should contact their GP in the first instance. For urgent mental health support, the NHS urgent mental health help page at nhs.uk/mental-health/feelings-symptoms-behaviours/feelings-and-symptoms/anxiety-fear-panic/mental-health-helplines provides further guidance. If symptoms are severe or there is any concern about immediate safety, NHS 111 can provide urgent advice, and 999 or accident and emergency should be used in a life-threatening situation.

Frequently Asked Questions